Renaissance Technologies - TRAVERE THERAPEUTICS INC ownership

TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of TRAVERE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$17,827
-25.4%
1,994,122
+28.2%
0.03%
-11.8%
Q2 2023$23,885
-50.5%
1,555,013
-27.5%
0.03%
-46.9%
Q1 2023$48,237
+43.9%
2,144,822
+34.6%
0.06%
+39.1%
Q4 2022$33,512
-99.9%
1,593,522
+5.7%
0.05%
-13.2%
Q3 2022$37,143,000
-7.5%
1,507,422
-9.0%
0.05%
+10.4%
Q2 2022$40,150,000
+14.8%
1,657,022
+22.1%
0.05%
+17.1%
Q1 2022$34,978,000
+8.4%
1,357,322
+30.5%
0.04%
+2.5%
Q4 2021$32,279,000
+7.3%
1,039,922
-16.2%
0.04%
+2.6%
Q3 2021$30,080,000
+20.5%
1,240,418
-27.5%
0.04%
+25.8%
Q2 2021$24,968,000
-37.1%
1,711,322
+7.7%
0.03%
-36.7%
Q1 2021$39,670,000
-21.8%
1,588,722
-14.7%
0.05%
-10.9%
Q4 2020$50,733,0001,861,4220.06%
Other shareholders
TRAVERE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Finepoint Capital LP 895,821$8,008,6403.99%
Deep Track Capital, LP 7,370,000$65,887,8002.54%
VR Adviser, LLC 2,623,677$23,455,6722.47%
Sio Capital Management, LLC 884,770$7,909,8442.45%
Kynam Capital Management, LP 957,502$8,560,0681.40%
MPM BioImpact LLC 552,846$4,942,4431.32%
ARMISTICE CAPITAL, LLC 7,500,000$67,050,0001.03%
Parkman Healthcare Partners LLC 577,494$5,162,7960.95%
Tri Locum Partners LP 251,702$2,250,2160.72%
Cheyne Capital Management (UK) LLP 26,200$234,2280.68%
View complete list of TRAVERE THERAPEUTICS INC shareholders